For the study ... show. The findings were published Monday in the Annals of Internal Medicine. There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug ...

A recent study reveals a surge in the use of GLP-1 medications, such as Ozempic and Wegovy, among younger age groups.

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

Related Massive study looks at benefits, risks of GLP-1 weight-loss drugs GLP-1 medications show promise in slowing ... GLP-1 drug use rose from 0.1% of the population in 2018 to 0.4% in 2022.

For this study, researchers analyzed U.S. federal research data in which people were asked about their GLP-1 prescriptions. Results showed that among people without diabetes, GLP-1 drug use rose ...

The rising use of glucagon-like peptide-1 (GLP ... of drug that mimics the glucagon-like peptide-1 hormone. It stimulates insulin secretion and reduces appetite, helping to control blood sugar and ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced ... Those are the findings of an observational study that claims to be the largest ever conducted on the ...

(KOLN) - Popular GLP-1 drugs have ... weight loss. The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may ...

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with significant ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...